{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T06:41:46Z","timestamp":1771915306135,"version":"3.50.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,12,20]],"date-time":"2013-12-20T00:00:00Z","timestamp":1387497600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s13318-013-0168-3","type":"journal-article","created":{"date-parts":[[2013,12,19]],"date-time":"2013-12-19T12:19:50Z","timestamp":1387455590000},"page":"243-253","source":"Crossref","is-referenced-by-count":12,"title":["The influence of comedication on tacrolimus blood concentration in patients subjected to kidney transplantation: a retrospective study"],"prefix":"10.1007","volume":"39","author":[{"given":"Neven","family":"Vavic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nemanja","family":"Rancic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktorija","family":"Dragojevic-Simic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biljana","family":"Draskovic-Pavlovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dubravko","family":"Bokonjic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ljiljana","family":"Ignjatovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Momir","family":"Mikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,12,20]]},"reference":[{"key":"168_CR1","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1111\/j.1600-6143.2012.04174.x","volume":"12","author":"RR Alloway","year":"2012","unstructured":"Alloway RR, Sadaka B, Trofe-Clark J et al (2012) A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients. Am J Transplant 12:2825\u20132831","journal-title":"Am J Transplant"},{"key":"168_CR2","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1093\/ndt\/gfg381","volume":"18","author":"D Anglicheau","year":"2003","unstructured":"Anglicheau D, Flamant M, Schlageter MH et al (2003) Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant 18:2409\u20132414","journal-title":"Nephrol Dial Transplant"},{"key":"168_CR3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF00561479","volume":"18","author":"JV Aranda","year":"1980","unstructured":"Aranda JV, Turmen T, Sasyniuk BI (1980) Pharmacokinetics of diuretics and methylxanthines in the neonate. Eur J Clin Pharmacol 18:55\u201363","journal-title":"Eur J Clin Pharmacol"},{"key":"168_CR4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-2125.2010.03815.x","volume":"71","author":"KA Barraclough","year":"2011","unstructured":"Barraclough KA, Isbel NM, Kirkpatrick CM et al (2011) Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients. Br J Clin Pharmacol 71:207\u2013223","journal-title":"Br J Clin Pharmacol"},{"key":"168_CR5","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2165\/11318080-000000000-00000","volume":"48","author":"K Benkali","year":"2009","unstructured":"Benkali K, Pr\u00e9maud A, Picard N et al (2009) Tacrolimus population pharmacokinetic-pharmacogenetic analysis and bayesian estimation in renal transplant recipients. Clin Pharmacokinet 48:805\u2013816","journal-title":"Clin Pharmacokinet"},{"key":"168_CR6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000258688","volume":"31","author":"V Bhatnagar","year":"2010","unstructured":"Bhatnagar V, Garcia EP, O\u2019Connor DT et al (2010) CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease. Am J Nephrol 31:95\u2013103","journal-title":"Am J Nephrol"},{"key":"168_CR7","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/FTD.0b013e3181a8f02a","volume":"31","author":"AM Borobia","year":"2009","unstructured":"Borobia AM, Romero I, Jimenez C et al (2009) Trough tacrolimus concentrations in the first week after kidney transplantation are related to acute rejection. Ther Drug Monit 31:436\u2013442","journal-title":"Ther Drug Monit"},{"key":"168_CR8","first-page":"814","volume":"53","author":"OE Brodde","year":"2003","unstructured":"Brodde OE, Kroemer HK (2003) Drug\u2013drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung 53:814\u2013822","journal-title":"Arzneimittelforschung"},{"key":"168_CR9","first-page":"17","volume-title":"Goodman & Gilman\u2019s the pharmacological basis of therapeutics","author":"ILO Buxton","year":"2011","unstructured":"Buxton ILO, Benet ZL (2011) Pharmacokinetics: molecular mechanisms of drug action. In: Brunton LL (ed) Goodman & Gilman\u2019s the pharmacological basis of therapeutics, 12th edn. McGraw-Hill Book Company, New York, pp 17\u201339","edition":"12"},{"key":"168_CR10","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1345\/aph.18409","volume":"33","author":"D Capone","year":"1999","unstructured":"Capone D, Gentile A, Imperatore P et al (1999) Effects of itraconazole on tacrolimus blood concentrations in a renal transplant recipient. Ann Pharmacother 33:1124\u20131125","journal-title":"Ann Pharmacother"},{"key":"168_CR11","first-page":"147","volume-title":"Kidney transplantation\u2014new perspectives","author":"CY Cheung","year":"2011","unstructured":"Cheung CY (2011) Pharmacogenetics and renal transplantation. In: Trzci\u0144ska M (ed) Kidney transplantation\u2014new perspectives. InTech, Rijeka, pp 147\u2013162"},{"key":"168_CR12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2125.1996.tb00181.x","volume":"41","author":"U Christians","year":"1996","unstructured":"Christians U, Schmidt G, Bader A et al (1996) Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol 41:187\u2013190","journal-title":"Br J Clin Pharmacol"},{"key":"168_CR13","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2165\/00003088-200241110-00003","volume":"41","author":"U Christians","year":"2002","unstructured":"Christians U, Jacobsen W, Benet LZ et al (2002) Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 41:813\u2013851","journal-title":"Clin Pharmacokinet"},{"key":"168_CR14","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1124\/dmd.105.008680","volume":"34","author":"Y Dai","year":"2006","unstructured":"Dai Y, Hebert MF, Isoherranen N et al (2006) Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 34:836\u2013847","journal-title":"Drug Metab Dispos"},{"key":"168_CR15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-200645010-00002","volume":"45","author":"AK Daly","year":"2006","unstructured":"Daly AK (2006) Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet 45:13\u201331","journal-title":"Clin Pharmacokinet"},{"key":"168_CR16","volume-title":"Therapeutic drugs","year":"1999","unstructured":"Dollery C (ed) (1999) Therapeutic drugs, 2nd edn. Churchill Livingstone, Edinburgh","edition":"2"},{"key":"168_CR17","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/FTD.0b013e31824b0bfb","volume":"34","author":"IR Dubbelboer","year":"2012","unstructured":"Dubbelboer IR, Pohanka A, Said R et al (2012) Quantification of tacrolimus and three demethylated metabolites in human whole blood using LC\u2013ESI-MS\/MS. Ther Drug Monit 34:134\u2013142","journal-title":"Ther Drug Monit"},{"issue":"25","key":"168_CR18","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","volume":"357","author":"H Ekberg","year":"2007","unstructured":"Ekberg H, Tedesco-Silva H, Demirbas A et al (2007) Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357(25):2562\u20132575","journal-title":"N Engl J Med"},{"key":"168_CR19","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/ndt\/12.8.1668","volume":"12","author":"G Filler","year":"1997","unstructured":"Filler G, Grygas R, Mai I et al (1997) Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. Nephrol Dial Transplant 12:1668\u20131671","journal-title":"Nephrol Dial Transplant"},{"key":"168_CR20","first-page":"939","volume-title":"Pharmacotherapy principles and practice","author":"S Gabardi","year":"2008","unstructured":"Gabardi S, Olyaei JA (2008) Solid organ transplantation. In: Chisholm-Burns MA, Wells BG, Schwinghammer TL (eds) Pharmacotherapy principles and practice. McGaw Hills Companies, Inc., New York, pp 939\u2013964"},{"key":"168_CR21","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1111\/j.1600-6143.2006.01518.x","volume":"6","author":"V Haufroid","year":"2006","unstructured":"Haufroid V, Wallemacq P, VanKerckhove V et al (2006) CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am J Transplant 6:2706\u20132713","journal-title":"Am J Transplant"},{"key":"168_CR22","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1345\/aph.18356","volume":"33","author":"MF Hebert","year":"1999","unstructured":"Hebert MF, Lam AY (1999) Diltiazem increases tacrolimus concentrations. Ann Pharmacother 33:680\u2013682","journal-title":"Ann Pharmacother"},{"key":"168_CR23","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1046\/j.0306-5251.2003.01882.x","volume":"56","author":"DA Hesselink","year":"2003","unstructured":"Hesselink DA, Ngyuen H, Wabbijn M et al (2003) Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. Br J Clin Pharmacol 56:327\u2013330","journal-title":"Br J Clin Pharmacol"},{"key":"168_CR24","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00007890-200201270-00028","volume":"73","author":"M Homma","year":"2002","unstructured":"Homma M, Itagaki F, Yuzawa K et al (2002) Effect of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation. Transplantation 73:303\u2013304","journal-title":"Transplantation"},{"key":"168_CR25","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.transproceed.2005.02.066","volume":"37","author":"K Hoshinaga","year":"2005","unstructured":"Hoshinaga K, Aikawa A, Murai M et al (2005) Regimen of tacrolimus-based immunosuppression with basiliximab, mycophenolate mofetil, and low-dose steroid reduces acute rejection in kidney transplants. Transplant Proc 37:1762\u20131763","journal-title":"Transplant Proc"},{"key":"168_CR26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2133\/dmpk.23.134","volume":"23","author":"K Hosohata","year":"2008","unstructured":"Hosohata K, Masuda S, Ogura Y et al (2008) Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5. Drug Metab Pharmacokinet 23:134\u2013138","journal-title":"Drug Metab Pharmacokinet"},{"issue":"Suppl. 3","key":"168_CR27","first-page":"27","volume":"13","author":"T Ishizaki","year":"1999","unstructured":"Ishizaki T, Horai Y (1999) Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Pharmacol Ther 13(Suppl. 3):27\u201336","journal-title":"Pharmacol Ther"},{"key":"168_CR28","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1016\/S0041-1345(02)03409-7","volume":"34","author":"F Itagaki","year":"2002","unstructured":"Itagaki F, Homma M, Yuzawa K et al (2002) Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation. Transplant Proc 34:2777\u20132778","journal-title":"Transplant Proc"},{"key":"168_CR29","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1248\/bpb.27.1694","volume":"27","author":"F Itagaki","year":"2004","unstructured":"Itagaki F, Homma M, Takara K et al (2004) Effect of rabeprazole on MDR1-mediated transport of Rhodamine 123 in Caco-2 and Hvr100-6 cells. Biol Pharm Bull 27:1694\u20131696","journal-title":"Biol Pharm Bull"},{"key":"168_CR30","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2133\/dmpk.22.328","volume":"22","author":"K Iwasaki","year":"2007","unstructured":"Iwasaki K (2007) Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet 22:328\u2013335","journal-title":"Drug Metab Pharmacokinet"},{"key":"168_CR31","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2215\/CJN.02860806","volume":"2","author":"H Jeong","year":"2007","unstructured":"Jeong H, Kaplan B (2007) Therapeutic monitoring of mycophenolate mofetil. Clin J Am Soc Nephrol 2:184\u2013191","journal-title":"Clin J Am Soc Nephrol"},{"key":"168_CR32","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0149-2918(02)85038-X","volume":"24","author":"B Kahan","year":"2002","unstructured":"Kahan B, Keown P, Levy G et al (2002) Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther 24:330\u2013350","journal-title":"Clin Ther"},{"key":"168_CR33","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1373\/clinchem.2005.050047","volume":"51","author":"LK Kamdem","year":"2005","unstructured":"Kamdem LK, Streit F, Zanger UM et al (2005) Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem 51:1374\u20131381","journal-title":"Clin Chem"},{"key":"168_CR34","volume-title":"Basic and clinical pharmacology","year":"2012","unstructured":"Katzung B, Masters S, Trevor A (eds) (2012) Basic and clinical pharmacology, 12th edn. McGraw-Hill Companies, Inc., New York","edition":"12"},{"key":"168_CR35","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/00007890-199610150-00009","volume":"62","author":"RP Kershner","year":"1996","unstructured":"Kershner RP, Fitzsimmons WE (1996) Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 62:920\u2013926","journal-title":"Transplantation"},{"key":"168_CR36","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.clpt.2006.09.009","volume":"80","author":"KA Kim","year":"2006","unstructured":"Kim KA, Park PW, Lee OJ et al (2006) Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. Clin Pharmacol Ther 80:646\u2013656","journal-title":"Clin Pharmacol Ther"},{"key":"168_CR37","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1742-7843.2012.00892.x","volume":"111","author":"IW Kim","year":"2012","unstructured":"Kim IW, Noh H, Ji E et al (2012) Identification of factors affecting tacrolimus level and 5-year clinical outcome in kidney transplant patients. Basic Clin Pharmacol Toxicol 111:217\u2013223","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"168_CR38","first-page":"1005","volume-title":"Goodman & Gilman\u2019s the pharmacological basis of therapeutics","author":"MA Krensky","year":"2011","unstructured":"Krensky MA, Bennett MW, Vincenti F (2011) Immunosuppressants, tolerogens and immunostimulants. In: Brunton LL (ed) Goodman & Gilman\u2019s the pharmacological basis of therapeutics, 12th edn. McGraw-Hill Book Company, New York, pp 1005\u20131031","edition":"12"},{"key":"168_CR39","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/ndt\/gfg555","volume":"19","author":"DRJ Kuypers","year":"2004","unstructured":"Kuypers DRJ, Vanrenterghem YFC (2004) Monoclonal antibodies in renal transplantation: old and new. Nephrol Dial Transplant 19:297\u2013299","journal-title":"Nephrol Dial Transplant"},{"key":"168_CR40","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0090-9556(25)06862-X","volume":"23","author":"A Lampen","year":"1995","unstructured":"Lampen A, Christians U, Guengerich FP et al (1995) Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 23:1315\u20131324","journal-title":"Drug Metab Dispos"},{"key":"168_CR41","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00467-009-1402-8","volume":"25","author":"S Leroy","year":"2010","unstructured":"Leroy S, Isapof A, Fargue S et al (2010) Tacrolimus nephrotoxicity: beware of the association of diarrhea, drug interaction and pharmacogenetics. Pediatr Nephrol 25:965\u2013969","journal-title":"Pediatr Nephrol"},{"key":"168_CR42","first-page":"58","volume":"2","author":"S Leroy","year":"2011","unstructured":"Leroy S, Fargue S, Bensman A et al (2011) Tacrolimus adverse events in transplant recipients with diarrhoea or calcium channel blockers: systematic review. Med Case Stud 2:58\u201368","journal-title":"Med Case Stud"},{"key":"168_CR43","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/tpj.2010.42","volume":"11","author":"JL Li","year":"2011","unstructured":"Li JL, Wang XD, Chen SY et al (2011) Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective. Pharmacogenomics J 11:300\u2013306","journal-title":"Pharmacogenomics J"},{"key":"168_CR44","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/01.TP.0000151766.73249.12","volume":"79","author":"IA Macphee","year":"2005","unstructured":"Macphee IA, Fredericks S, Mohamed M et al (2005) Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation 79:499\u2013502","journal-title":"Transplantation"},{"key":"168_CR45","doi-asserted-by":"crossref","first-page":"E217","DOI":"10.1111\/j.1399-3046.2011.01559.x","volume":"16","author":"M Maguire","year":"2012","unstructured":"Maguire M, Franz T, Hains DS (2012) A clinically significant interaction between tacrolimus and multiple proton pump inhibitors in a kidney transplant recipient. Pediatr Transplant 16:E217\u2013E220","journal-title":"Pediatr Transplant"},{"key":"168_CR46","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.pharmthera.2006.04.006","volume":"112","author":"S Masuda","year":"2006","unstructured":"Masuda S, Inui K (2006) An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther 112:184\u2013198","journal-title":"Pharmacol Ther"},{"key":"168_CR47","volume-title":"AHFS drug information 2011","year":"2011","unstructured":"McEvoy GK (ed) (2011) AHFS drug information 2011. American Society of Health-System Pharmacists, Bethesda"},{"key":"168_CR48","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/bdd.544","volume":"28","author":"M Miura","year":"2007","unstructured":"Miura M, Inoue K, Kagaya H et al (2007) Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. Biopharm Drug Dispos 28:167\u2013175","journal-title":"Biopharm Drug Dispos"},{"key":"168_CR49","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2710.2010.01163.x","volume":"36","author":"M Miura","year":"2011","unstructured":"Miura M, Niioka T, Kagaya H et al (2011) Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1\u00a0year after renal transplantation. J Clin Pharm Ther 36:208\u2013216","journal-title":"J Clin Pharm Ther"},{"key":"168_CR50","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2165\/00003495-200059020-00021","volume":"59","author":"GL Plosker","year":"2000","unstructured":"Plosker GL, Foster RH (2000) Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 59:323\u2013389","journal-title":"Drugs"},{"key":"168_CR51","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/S0021-9258(18)53221-X","volume":"268","author":"T Saeki","year":"1993","unstructured":"Saeki T, Ueda K, Tanigawara Y et al (1993) Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 268:6077\u20136080","journal-title":"J Biol Chem"},{"key":"168_CR52","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1046\/j.1432-1327.1998.2510252.x","volume":"251","author":"A Seelig","year":"1998","unstructured":"Seelig A (1998) A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 251:252\u2013261","journal-title":"Eur J Biochem"},{"key":"168_CR53","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1600-6143.2012.04327.x","volume":"13","author":"FS Shihab","year":"2013","unstructured":"Shihab FS, Lee ST, Smith LD et al (2013) Effect of corticosteroid withdrawal on tacrolimus and mycophenolate mofetil exposure in a randomized multicenter study. Am J Transplant 13:474\u2013484","journal-title":"Am J Transplant"},{"key":"168_CR54","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1097\/00007890-200211270-00014","volume":"74","author":"T Shimada","year":"2002","unstructured":"Shimada T, Terada A, Yokogawa K et al (2002) Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. Transplantation 74:1419\u20131424","journal-title":"Transplantation"},{"key":"168_CR55","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","volume":"43","author":"CE Staatz","year":"2004","unstructured":"Staatz CE, Tett SE (2004) Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 43:623\u2013653","journal-title":"Clin Pharmacokinet"},{"key":"168_CR56","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/ndt\/16.9.1905","volume":"16","author":"C Staatz","year":"2001","unstructured":"Staatz C, Taylor P, Tett S (2001) Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol Dial Transplant 16:1905\u20131909","journal-title":"Nephrol Dial Transplant"},{"key":"168_CR57","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00228-011-1150-0","volume":"68","author":"P Stratta","year":"2012","unstructured":"Stratta P, Quaglia M, Cena T et al (2012) The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation. Eur J Clin Pharmacol 68:671\u2013680","journal-title":"Eur J Clin Pharmacol"},{"key":"168_CR58","unstructured":"Sweetman SC, ed. Martindale: The Complete Drug Reference 36. [CD-ROM] London: Pharmaceutical Press; 2009"},{"key":"168_CR59","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1345\/aph.1D366","volume":"38","author":"K Takahashi","year":"2004","unstructured":"Takahashi K, Motohashi H, Yonezawa A et al (2004) Lansoprazole\u2013tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism. Ann Pharmacother 38:791\u2013794","journal-title":"Ann Pharmacother"},{"key":"168_CR60","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2133\/dmpk.22.441","volume":"22","author":"K Takahashi","year":"2007","unstructured":"Takahashi K, Yano I, Fukuhara Y et al (2007) Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient. Drug Metab Pharmacokinet 22:441\u2013444","journal-title":"Drug Metab Pharmacokinet"},{"key":"168_CR61","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/FPC.0b013e3283557c74","volume":"22","author":"S Terrazzino","year":"2012","unstructured":"Terrazzino S, Quaglia M, Stratta P et al (2012) The effect of CYP3A5 6986A\u00a0>\u00a0G and ABCB1 3435C\u00a0>\u00a0T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis. Pharmacogenetics Genomics 22:642\u2013645","journal-title":"Pharmacogenetics Genomics"},{"key":"168_CR62","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/01.TP.0000090753.99170.89","volume":"76","author":"E Thervet","year":"2003","unstructured":"Thervet E, Anglicheau D, King B et al (2003) Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76:1233\u20131235","journal-title":"Transplantation"},{"key":"168_CR63","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.2146\/ajhp060080","volume":"63","author":"KN Utecht","year":"2006","unstructured":"Utecht KN, Hiles JJ, Kolesar J (2006) Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors. Am J Health Syst Pharm 63:2340\u20132348","journal-title":"Am J Health Syst Pharm"},{"key":"168_CR64","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/clinchem\/48.10.1668","volume":"48","author":"RH Schaik van","year":"2002","unstructured":"van Schaik RH, van der Heiden IP, van den Anker JN et al (2002) CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 48:1668\u20131671","journal-title":"Clin Chem"},{"key":"168_CR65","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1034\/j.1399-0012.2001.150203.x","volume":"15","author":"E Vasquez","year":"2001","unstructured":"Vasquez E, Pollak R, Benedetti E (2001) Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients. Clin Transplant 15:95\u201399","journal-title":"Clin Transplant"},{"key":"168_CR66","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1742-7843.2009.00535.x","volume":"106","author":"RM Velickovic-Radovanovic","year":"2010","unstructured":"Velickovic-Radovanovic RM, Paunovic G, Mikov M et al (2010) Clinical pharmacokinetics of tacrolimus after the first oral administration in renal transplant recipients on triple immunosuppressive therapy. Basic Clin Pharmacol Toxicol 106:505\u2013510","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"168_CR67","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.genm.2011.01.003","volume":"8","author":"R Velickovi\u0107-Radovanovi\u0107","year":"2011","unstructured":"Velickovi\u0107-Radovanovi\u0107 R, Mikov M, Paunovi\u0107 G et al (2011) Gender differences in pharmacokinetics of tacrolimus and their clinical significance in kidney transplant recipients. Gend Med 8:23\u201331","journal-title":"Gend Med"},{"key":"168_CR68","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2165\/00003088-199529060-00003","volume":"29","author":"R Venkataramanan","year":"1995","unstructured":"Venkataramanan R, Swaminathan A, Prasad T et al (1995) Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 29:404\u2013430","journal-title":"Clin Pharmacokinet"},{"key":"168_CR69","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/FTD.0b013e318198d092","volume":"31","author":"P Wallemacq","year":"2009","unstructured":"Wallemacq P, Armstrong VW, Brunet M et al (2009) Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit 31:139\u2013152","journal-title":"Ther Drug Monit"},{"key":"168_CR70","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11771-005-0419-9","volume":"12","author":"N Xin-Min","year":"2005","unstructured":"Xin-Min N, Rong G, Hong-Shan Z et al (2005) Influence of CYP3A5 polymorphism on tacrolimus blood concentrations in renal transplant patients. J Cent South Univ Technol. 12:310\u2013313","journal-title":"J Cent South Univ Technol."},{"key":"168_CR71","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0009-9236(95)90192-2","volume":"58","author":"S Yasuda","year":"1995","unstructured":"Yasuda S, Horai Y, Tomono Y et al (1995) Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4\u2032-hydroxylation status. Clin Pharmacol Ther 58:143\u2013154","journal-title":"Clin Pharmacol Ther"},{"key":"168_CR72","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1097\/TP.0b013e318249b180","volume":"93","author":"W Zhao","year":"2012","unstructured":"Zhao W, Baudouin V, Fakhoury M et al (2012a) Pharmacokinetic interaction between tacrolimus and amlodipine in a renal transplant child. Transplantation 93:e29\u2013e30","journal-title":"Transplantation"},{"key":"168_CR73","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/FTD.0b013e318271b6e6","volume":"34","author":"W Zhao","year":"2012","unstructured":"Zhao W, Fakhoury M, Maisin A et al (2012b) Pharmacogenetic determinant of the drug interaction between tacrolimus and omeprazole. Ther Drug Monit 34:739\u2013741","journal-title":"Ther Drug Monit"},{"key":"168_CR74","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/11318030-000000000-00000","volume":"48","author":"SF Zhou","year":"2009","unstructured":"Zhou SF (2009) Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet 48:689\u2013723","journal-title":"Clin Pharmacokinet"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-013-0168-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-013-0168-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-013-0168-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T07:58:12Z","timestamp":1746086292000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-013-0168-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,20]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["168"],"URL":"https:\/\/doi.org\/10.1007\/s13318-013-0168-3","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,20]]}}}